专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050256202A1 Process for preparing atazanavir bisulfate and novel forms 有权
标题翻译：制备阿扎那韦硫酸氢盐和新型形式的方法
公开(公告)号：US20050256202A1
公开(公告)日：2005-11-17
申请号：US11119558
申请日：2005-05-02
申请人： Soojin Kim , Bruce Lotz , Mary Malley , Jack Gougoutas , Martha Davidovich , Sushil Srivastava
发明人： Soojin Kim , Bruce Lotz , Mary Malley , Jack Gougoutas , Martha Davidovich , Sushil Srivastava
IPC分类号： A61K31/16 , C07C231/02 , C07C243/26 , C07D213/42
CPC分类号： C07D213/42
摘要： A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.
摘要翻译：提供了一种制备HIV蛋白酶抑制剂阿扎那韦硫酸氢盐的方法，其中阿扎那韦游离碱的溶液与浓硫酸反应的量与小于约15重量％的游离碱反应，阿扎那韦的A型晶体种子将硫酸氢盐加入到反应混合物中，并且以硫酸氢盐形式的结晶，按照立方式以增加的速率以多个阶段多次加入另外的浓硫酸，以实现阿扎那韦硫酸氢盐的形式A晶体的形成。还提供了制备作为图案C材料的阿扎那韦硫酸氢盐的方法。还提供了一种新型形式的阿扎那韦硫酸氢盐，其为E3型，其是来自乙醇的硫酸氢盐的高度结晶的三乙醇盐溶剂合物。

2. 发明申请

US20110124689A1 PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS 有权
标题翻译：制备ATAZANAVIR BISULFATE和新型的方法
公开(公告)号：US20110124689A1
公开(公告)日：2011-05-26
申请号：US12900588
申请日：2010-10-08
申请人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
发明人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
IPC分类号： A61K31/4418 , C07D213/42 , A61P31/12
CPC分类号： C07D213/42
摘要： A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate.A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.
摘要翻译：提供了一种制备HIV蛋白酶抑制剂阿扎那韦硫酸氢盐的方法，其中阿扎那韦游离碱的溶液与浓硫酸反应的量与小于约15重量％的游离碱反应，阿扎那韦的A型晶体种子将硫酸氢盐加入到反应混合物中，并且以硫酸氢盐形式的结晶，按照立方式以增加的速率以多个阶段多次加入另外的浓硫酸，以实现阿扎那韦硫酸氢盐的形式A晶体的形成。还提供了制备作为图案C材料的阿扎那韦硫酸氢盐的方法。还提供了一种新型形式的阿扎那韦硫酸氢盐，其为E3型，其是来自乙醇的硫酸氢盐的高度结晶的三乙醇盐溶剂合物。

3. 发明授权

US07838678B2 Process for preparing atazanavir bisulfate and novel forms 有权
公开(公告)号：US07838678B2
公开(公告)日：2010-11-23
申请号：US12360468
申请日：2009-01-27
申请人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
发明人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
IPC分类号： C07D213/56
CPC分类号： C07D213/42
摘要： A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate.A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.

4. 发明申请

US20090203630A1 PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS 有权
标题翻译：制备ATAZANAVIR BISULFATE和新型的方法
公开(公告)号：US20090203630A1
公开(公告)日：2009-08-13
申请号：US12360468
申请日：2009-01-27
申请人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
发明人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
IPC分类号： A61K38/05 , C07C243/18 , A61P31/12
CPC分类号： C07D213/42
摘要： A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate.A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.
摘要翻译：提供了一种制备HIV蛋白酶抑制剂阿扎那韦硫酸氢盐的方法，其中阿扎那韦游离碱的溶液与浓硫酸反应的量与小于约15重量％的游离碱反应，阿扎那韦的A型晶体种子将硫酸氢盐加入到反应混合物中，并且以硫酸氢盐形式的结晶，按照立方式以增加的速率以多个阶段多次加入另外的浓硫酸，以实现阿扎那韦硫酸氢盐的形式A晶体的形成。还提供了制备作为图案C材料的阿扎那韦硫酸氢盐的方法。还提供了一种新型形式的阿扎那韦硫酸氢盐，其为E3型，其是来自乙醇的硫酸氢盐的高度结晶的三乙醇盐溶剂合物。

5. 发明授权

US08513428B2 Process for preparing atazanavir bisulfate and novel forms 有权
标题翻译：制备阿扎那韦硫酸氢盐和新型形式的方法
公开(公告)号：US08513428B2
公开(公告)日：2013-08-20
申请号：US12900588
申请日：2010-10-08
申请人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
发明人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
IPC分类号： C07D213/56 , A61K31/44
CPC分类号： C07D213/42
摘要： A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate.A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.
摘要翻译：提供了一种制备HIV蛋白酶抑制剂阿扎那韦硫酸氢盐的方法，其中阿扎那韦游离碱的溶液与浓硫酸反应的量与少于约15重量％的游离碱反应，阿扎那韦的A型晶体种子将硫酸氢盐加入到反应混合物中，并且以硫酸氢盐形式的结晶，按照立方式以增加的速率以多个阶段多次加入另外的浓硫酸，以实现阿扎那韦硫酸氢盐的形式A晶体的形成。还提供了制备作为图案C材料的阿扎那韦硫酸氢盐的方法。还提供了一种新型形式的阿扎那韦硫酸氢盐，其为E3型，其是来自乙醇的硫酸氢盐的高度结晶的三乙醇盐溶剂合物。

6. 发明授权

US07829720B2 Process for preparing atazanavir bisulfate and novel forms 有权
标题翻译：制备阿扎那韦硫酸氢盐和新型形式的方法
公开(公告)号：US07829720B2
公开(公告)日：2010-11-09
申请号：US11119558
申请日：2005-05-02
申请人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
发明人： Soojin Kim , Bruce T. Lotz , Mary F. Malley , Jack Z. Gougoutas , Martha Davidovich , Sushil K. Srivastava
IPC分类号： C07D213/56
CPC分类号： C07D213/42
摘要： A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.
摘要翻译：提供了一种制备HIV蛋白酶抑制剂阿扎那韦硫酸氢盐的方法，其中阿扎那韦游离碱的溶液与浓硫酸反应的量与小于约15重量％的游离碱反应，阿扎那韦的A型晶体种子将硫酸氢盐加入到反应混合物中，并且以硫酸氢盐形式的结晶，按照立方式以增加的速率以多个阶段多次加入另外的浓硫酸，以实现阿扎那韦硫酸氢盐的形式A晶体的形成。还提供了制备作为图案C材料的阿扎那韦硫酸氢盐的方法。还提供了一种新型形式的阿扎那韦硫酸氢盐，其为E3型，其是来自乙醇的硫酸氢盐的高度结晶的三乙醇盐溶剂合物。

7. 发明申请

US20060235020A1 Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein 审中-公开
标题翻译：制备4 - [[5 - [（环丙基氨基）羰基] -2-甲基苯基]氨基] -5-甲基-N-丙基吡咯并[2,1-f] [1,2,4]三嗪-6- 甲酰胺和其中产生的新颖的稳定形式
公开(公告)号：US20060235020A1
公开(公告)日：2006-10-19
申请号：US11398102
申请日：2006-04-04
申请人： Soojin Kim , Mary Malley , Zhongping Shi
发明人： Soojin Kim , Mary Malley , Zhongping Shi
IPC分类号： C07D253/08 , A61K31/53
CPC分类号： C07D487/04
摘要： Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also provided.
摘要翻译：提供了选择性和一致地选择性制备新的稳定结晶盐形式的方法，即制备甲磺酸盐的N-1型，和p38激酶抑制剂4的盐酸盐的N-1和N-4型 - [[5 - [（环丙基氨基）羰基] -2-甲基苯基]氨基] -5-甲基-N-丙基吡咯并[2,1-f] [1,2,4]三嗪-6-甲酰胺。该方法优选使用包含甲酸/丙酮和甲酸/甲基乙基酮的溶剂体系，其产生具有合适流动性和所需粒径的晶体，并且也可以使用溶剂如N，N-二甲基甲酰胺和N，N-二甲基乙酰胺。上述游离碱的甲磺酸盐的盐酸盐形式的N-1型和N-4型结晶的新型N-1晶体和形式N-1晶体，含有这种新形式的药物组合物和治疗方法还提供p38激酶相关病症，包括类风湿性关节炎。

8. 发明申请

US20180211830A1 METHOD OF MANUFACTURING A SEMICONDUCTOR DEVICE AND A CLEANING COMPOSITION FOR AN ADHESIVE LAYER 审中-公开
公开(公告)号：US20180211830A1
公开(公告)日：2018-07-26
申请号：US15841946
申请日：2017-12-14
申请人： Hoyoung Kim , Hyo-Sun Lee , Soojin Kim , Keonyoung Kim , Jinhye Bae , Hoon Han , Tae Soo Kwon , Jung Hun Lim
发明人： Hoyoung Kim , Hyo-Sun Lee , Soojin Kim , Keonyoung Kim , Jinhye Bae , Hoon Han , Tae Soo Kwon , Jung Hun Lim
IPC分类号： H01L21/02 , C11D7/26 , C11D7/08 , C11D7/32 , C11D11/00 , H01L21/683 , H01L23/00
CPC分类号： H01L21/02068 , C11D7/08 , C11D7/261 , C11D7/264 , C11D7/266 , C11D7/3209 , C11D7/3218 , C11D11/0047 , H01L21/02057 , H01L21/304 , H01L21/30604 , H01L21/30625 , H01L21/6835 , H01L24/05 , H01L24/06 , H01L24/11 , H01L24/13 , H01L24/16 , H01L24/17 , H01L24/81 , H01L2221/68327 , H01L2221/68381 , H01L2224/03002 , H01L2224/0401 , H01L2224/0557 , H01L2224/05624 , H01L2224/05647 , H01L2224/06181 , H01L2224/1181 , H01L2224/13111 , H01L2224/13139 , H01L2224/13147 , H01L2224/16145 , H01L2224/16227 , H01L2224/17181 , H01L2224/81193 , H01L2224/81815 , H01L2224/94 , H01L2225/06513 , H01L2225/06517 , H01L2225/06541 , H01L2225/06565 , H01L2924/10252 , H01L2924/10253 , H01L2924/15311 , H01L2924/3512 , H01L2924/37001 , H01L2224/11 , H01L2224/03
摘要： Embodiments of the inventive concepts provide a method of manufacturing a semiconductor device and a cleaning composition for an adhesive layer. The method includes preparing a semiconductor substrate to which an adhesive layer adheres, removing the adhesive layer from the semiconductor substrate, and applying a cleaning composition to the semiconductor substrate to remove a residue of the adhesive layer. The cleaning composition includes a solvent including a ketone compound and having a content that is equal to or greater than 40 wt % and less than 90 wt %, quaternary ammonium salt, and primary amine.

9. 发明申请

US20120108594A1 PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPYLPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN 审中-公开
标题翻译：制备4 - [[5 - [（环丙基氨基）羰基] -2-甲基苯基]氨基] -5-甲基-N-丙基吡咯并[2,1-f] [1,2,4]三氮杂- 碳酰胺和生产的新型稳定形式
公开(公告)号：US20120108594A1
公开(公告)日：2012-05-03
申请号：US13293204
申请日：2011-11-10
申请人： Soojin Kim , Mary F. Malley , Zhongping Shi
发明人： Soojin Kim , Mary F. Malley , Zhongping Shi
IPC分类号： A61K31/53 , A61P29/00 , A61P11/06 , A61P11/00 , A61P19/02 , A61P1/00 , A61P19/10 , A61P17/06 , A61P37/06 , A61P9/10 , C07D487/04 , A61P3/10
CPC分类号： C07D487/04
摘要： Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well.Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also provided.
摘要翻译：提供了选择性和一致地选择性制备新的稳定结晶盐形式的方法，即制备甲磺酸盐的N-1型，和p38激酶抑制剂4的盐酸盐的N-1和N-4型 - [[5 - [（环丙基氨基）羰基] -2-甲基苯基]氨基] -5-甲基-N-丙基吡咯并[2,1-f] [1,2,4]三嗪-6-甲酰胺。该方法优选使用包含甲酸/丙酮和甲酸/甲基乙基酮的溶剂体系，其产生具有合适流动性和所需粒径的晶体，并且也可以使用溶剂如N，N-二甲基甲酰胺和N，N-二甲基乙酰胺。上述游离碱的甲磺酸盐的盐酸盐形式的N-1型和N-4型结晶的新型N-1晶体和形式N-1晶体，含有这种新形式的药物组合物和治疗方法还提供p38激酶相关病症，包括类风湿性关节炎。

10. 发明申请

US20110166352A1 PROCESS FOR MAKING STERILE ARIPIPRAZOLE OF DESIRED MEAN PARTICLE SIZE 审中-公开
标题翻译：制备所需平均颗粒尺寸的异丙嗪的方法
公开(公告)号：US20110166352A1
公开(公告)日：2011-07-07
申请号：US13046138
申请日：2011-03-11
申请人： Margaret M. Gleeson , Soojin Kim , Donald C. Kientzler , San Kiang
发明人： Margaret M. Gleeson , Soojin Kim , Donald C. Kientzler , San Kiang
IPC分类号： C07D401/12
CPC分类号： A61J3/02 , B01D9/0009 , B01D9/005 , B01D9/0054 , B01D9/0063 , B01D9/0081 , B01J2/06 , C07D215/227
摘要： A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks.
摘要翻译：提供了一种制备平均粒径小于100微米但优选大于25微米的无菌阿立哌唑的方法，其采用冲击射流结晶方法。所得粒度的阿立哌唑可用于形成无菌冷冻干燥的阿立哌唑制剂，其在用水和肌内注射后，在至少约一周至多达八周的时间内释放阿立哌唑。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式